Grifols (GRFS) Cash from Financing Activities (2010 - 2020)
Grifols' (GRFS) quarterly Cash from Financing Activities came in at -$121.5 million in Q1 2020, down 93.07% YoY from -$1.8 billion in Q2 2019, and up 54.2% on a QoQ basis from -$265.2 million in Q4 2019.
Grifols (GRFS) Cash from Financing Activities (2010 - 2020) Analysis & Trends
Grifols (GRFS) has 11 years of Cash from Financing Activities data on file, last reported at -$121.5 million in Q1 2020.
- Quarterly Cash from Financing Activities fell 93.07% year-over-year to -$121.5 million in Q1 2020, while the trailing twelve-month figure through Mar 2020 was -$356.2 million (down 120.86% YoY) and the FY2025 annual result came in at -$615.8 million, up 57.6% from the prior year.
- Cash from Financing Activities improved to -$121.5 million in Q1 2020, from -$265.2 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $1.8 billion in Q4 2017 to a low of -$265.2 million in Q4 2019.
- A 5-year average of $236.6 million and a median of -$62.9 million in 2019 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2017 — Cash from Financing Activities jumped 1301.8% — and 2019, when it tumbled 503.89%.
- Tracing GRFS's Cash from Financing Activities over 5 years: stood at -$146.6 million in 2016, then soared by 1301.8% to $1.8 billion in 2017, then slumped by 94.7% to $93.4 million in 2018, then slumped by 383.88% to -$265.2 million in 2019, then soared by 54.2% to -$121.5 million in 2020.
- The last three Cash from Financing Activities figures came in at -$121.5 million (Q1 2020), -$265.2 million (Q4 2019), and -$62.9 million (Q1 2019), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | -8.78 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -5.05 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 1.76 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | -2.02 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -3.89 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | -1.48 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 2.34 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -3.66 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Grifols | 5.45 Bn | 4.45 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | -121.48 Mn |
| Mar 31, 2020 | -121.48 Mn |
| Dec 31, 2019 | -265.22 Mn |
| Dec 31, 2019 | -265.22 Mn |
| Mar 31, 2019 | -62.92 Mn |
| Mar 31, 2019 | -62.92 Mn |
| Dec 31, 2018 | 93.43 Mn |
| Dec 31, 2018 | 93.43 Mn |
| Jun 30, 2018 | -207.36 Mn |
| Jun 30, 2018 | -207.36 Mn |
| Mar 31, 2018 | 15.58 Mn |
| Mar 31, 2018 | 15.58 Mn |
| Dec 31, 2017 | 1.76 Bn |
| Dec 31, 2017 | 1.76 Bn |
| Jun 30, 2017 | -97.45 Mn |
| Jun 30, 2017 | -97.45 Mn |
| Mar 31, 2017 | 1.67 Bn |
| Mar 31, 2017 | 1.67 Bn |
| Dec 31, 2016 | -146.57 Mn |
| Dec 31, 2016 | -146.57 Mn |